The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 21, 2023
Filed:
Dec. 13, 2018
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Lin Yan, East Brunswick, NJ (US);
Pei Huo, Millburn, NJ (US);
Ahmet Kekec, Hoboken, NJ (US);
Danqing D. Feng, Green Brook, NJ (US);
Yuping Zhu, Basking Ridge, NJ (US);
Dmitri Pissarnitski, Scotch Plains, NJ (US);
Chris Moyes, Westfiled, NJ (US);
Songnian Lin, Holmdel, NJ (US);
Lin Yan, East Brunswick, NJ (US);
Pei Huo, Millburn, NJ (US);
Ahmet Kekec, Hoboken, NJ (US);
Danqing D. Feng, Green Brook, NJ (US);
Yuping Zhu, Basking Ridge, NJ (US);
Dmitri Pissarnitski, Scotch Plains, NJ (US);
Chris Moyes, Westfiled, NJ (US);
Songnian Lin, Holmdel, NJ (US);
MERCK SHARP & DOHME LLC, Rahway, NJ (US);
Abstract
The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally comprise a fatty chain (e.g., a C8-30 fatty chain), wherein when said insulin molecule is conjugated both to a C8-30 fatty chain and one or more separate ligands that each include a saccharide, said C8-30 fatty chain is linked to insulin molecule only, and wherein when the framework or ligand comprises a fatty chain the insulin molecule is conjugated to two or more separate ligands. In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.